R&D
GEXVal Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’
2024/12/16
GEXVal Inc.16 December, 2024 We are delighted to announce that GEXVal Inc.'s planned global Phase 2a Proof of […]
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia
2024/7/1
GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]
GEXVal Sponsors SLTBR 2024 35th Annual Meeting
2024/6/18
GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]
GEXVal Inc. Announces Collaboration with FRAXA-DVI
2023/2/28
GEXVal Inc.February 28, 2023 GEXVal Inc. is pleased to announce that we have initiated a collaboration project […]
Phase 1 Study of GXV-001 in Australia: Start of Repeated-Dose Study
2023/2/15
GEXVal Inc.February 15, 2023 Phase 1 Study of GXV-001 in Australia: Start of Repeated-Dose Study GEXVal Inc. […]